NEW YORK (Reuters) - The U.S. pharmaceutical industry is pushing to revamp the new law that allows Medicare to negotiate ...

There is more to the comparison, and in the sections below, we discuss why we think BMY will outperform JNJ in the next three ...

Nobody can predict the future, but it's not hard to imagine increasing pharmaceutical sales. In 2022, prescription drug ...

Bristol Myers Squibb Co. is challenging a federal health agency for denying its plan to implement a rebate model for its ...

It's a disease that is most common in people in their 70s, more common in women, and almost never seen below the age of 50.

I was recently diagnosed with polymyalgia rheumatica after weeks of intense muscle pain. I’m a 67-year-old female in otherwise good health. My doctor prescribed prednisone, which immediately ...

Laboratory testing for inflammation, such as the C-reactive protein test and the erythrocyte sedimentation rate, are almost ...

Bristol Myers Squibb has executed another round of layoffs in its ongoing cost-savings push. | Bristol Myers Squibb has ...

过去几年，百时美施贵宝Bristol Myers Squibb（$百时美施贵宝(BMY)$）一直处于专利悬崖的坠落过程中。由于两款重要药物——抗癌药物Revlimid（曾经的畅销产品）和Abraxane失去专利保护，公司财务业绩随之下滑。所幸的是，百时美施贵宝已经反弹，营收重回增长轨道。 但值得注意的是，未来几年，这家制药巨头仍将面临更多的专利悬崖。 百时美施贵宝仍未摆脱困境 今年9月，百时美施贵 ...

The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and ...

Research analysts at William Blair issued their Q1 2025 EPS estimates for shares of Bristol-Myers Squibb in a note issued to investors on Monday, November 18th. William Blair analyst M. Phipps ...

Inmates in Nevada prisons are being denied necessary medical care and medications, according to providers and a memo provided ...